ID-KORE-POWER/CLEANHILL
29.6.2021 14:02:12 CEST | Business Wire | Press release
KORE Power, Inc., (“KORE Power” or “KORE”) the leading U.S.-based developer of battery cell technology for the energy storage and electric transportation industries, announced that it has formed a strategic partnership with Cleanhill Partners (“Cleanhill”), a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization. Cleanhill has invested in KORE Power as part of the strategic partnership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005233/en/
Rakesh Wilson and Ash Upadhyaya, founders of Cleanhill, have joined KORE Power as special advisors to Founder and CEO Lindsay Gorrill. As veterans of the energy finance and investment sector, Rakesh and Ash will guide KORE’s strategy on growth and investment opportunities.
“Rakesh and Ash bring over 40 years of combined experience in ESG, power, energy and infrastructure,” said CEO Lindsay Gorrill. “We are excited to partner with them to tap into their rich experience to position KORE as the leader in the energy transition sector.”
Ash Upadhyaya is a founder and Managing Partner at Cleanhill Partners. He has over 20 years of experience in private equity and engineering, focusing on the energy value chain. Ash was a Managing Director at Centerbridge Partners and a Director at KKR. He has engineering degrees from Stanford University and the University of Mumbai and an MBA from Stanford University.
“I’m thrilled to work with KORE Power to expand the design and manufacturing of lithium-ion battery cells in the U.S.,” said Ash. “Through my experience with energy storage, I see the critical role that batteries will play in the clean energy transition. I look forward to adding value to KORE’s expert team.”
Rakesh Wilson has over 20 years of energy finance and private equity experience and is a founder and Managing Partner at Cleanhill Partners. He previously served as a Senior Partner at Apollo Global Management and led private equity investments across the energy value chain. Rakesh was also with Morgan Stanley’s Commodities Division and Goldman Sachs’ investment banking and equity research divisions. He graduated from the University of Texas at Austin and received his MBA from INSEAD, Fontainebleau, France.
“Working with KORE Power is a natural extension of my work on battery storage projects, renewable infrastructure, distributed generation, energy trading funds and carbon offsets,” said Rakesh. “The lithium-ion cell is at the center of the clean energy future, and I look forward to accelerating the clean energy transition by working with KORE.”
Evercore served as financial advisor to KORE Power and Kirkland & Ellis LLP served as legal counsel to Cleanhill Partners.
ABOUT KORE Power
KORE Power, Inc., is a leading US-based developer of battery cell technology for the clean energy industry, serving energy storage, e-mobility, utility, industrial and mission-critical markets across the globe. KORE Power designs and manufactures its proprietary NMC and LFP cells, VDA modules and packs, optimized by the battery management system. Through its global partnerships, KORE designs and manufactures top-tier energy storage systems (ESS).
KORE Power’s differentiated approach provides customers with direct access, unparalleled service, superior technology, and Tier 1 product availability. We care about building sustainable communities, clean energy jobs and green economic expansion. KORE Power is proud to offer a functional solution to real-world problems that fulfill growing market demand and contribute to a zero-carbon future. For more information, visit www.korepower.com .
ABOUT Cleanhill Partners
Cleanhill Partners is a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization. We invest in scalable businesses with visibility into revenues, earnings and cash flow growth. We leverage our thesis-driven approach and our operational expertise to enhance value in each of our investments. Our long-term investment philosophy to decarbonize and create value aligns our stakeholders, our communities and the businesses we invest in. The firm has offices in New York and Houston. To learn more, please visit www.cleanhillpartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005233/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom